Matthew W. Davis

Matthew W. Davis, MD, RPh

Research and development executive with 9 FDA approvals, plus 3 programs approved after he moved on. Head of R&D at Aquestive and global head of branded R&D at Endo. Chief Operating Officer and Chief Medical Officer at Tiziana Life Sciences. Inventor on all 17 Orange Book patents for Colcrys.

EmailLinkedIn

9

FDA approvals

17

Orange Book patents for Colcrys

$3.2B

Sale of URL Pharma to Takeda

1,100+

Citations of published work

About

Physician and pharmacist. My experience runs from preclinical work through launch and includes business development, capital raising, investor relations, and work with Congress.

I design and build AI tools for drug development work myself.

Experience

  1. 2025 to Present

    Chief Development Officer

    Aquestive Therapeutics, Warren, NJ

    Head of R&D and head of search and evaluation.

  2. 2024 to 2025

    Chief Medical Officer

    Neuvivo, Palo Alto, CA

    Reached agreement with FDA on an approval pathway for NP001 in ALS, ending a 7-year regulatory standstill.

  3. 2022 to 2024

    Chief Operating Officer and Chief Medical Officer

    Tiziana Life Sciences, London, UK (based in Doylestown, PA)

    Joined as Chief Medical Officer and was promoted to Chief Operating Officer within 6 months, holding both roles. Saved $12M in the first year by reprioritizing the portfolio and restored NASDAQ compliance.

  4. 2017 to 2022

    Global Head of Branded R&D; Chief Scientific Officer (previously Chief Medical Officer)

    Endo Pharmaceuticals, Malvern, PA

    Led an R&D organization of 1,200 people. Cut R&D cost by $55M a year and secured BLA approval for QWO 2 months ahead of the PDUFA date.

  5. 2014 to 2016

    Chief Medical Officer

    Lupin, Baltimore, MD

    Conceived the Impleko 505(b)(2) program and led the program and team until leaving Lupin (FDA approved Impleko in 2020). Led the due diligence behind the acquisition of Solosec.

  6. 2005 to 2013

    Chief Medical Officer and Senior Vice President

    URL Pharma, Philadelphia, PA

    Won FDA approval of Colcrys in 3 indications. Member of the executive team that sold the company to Takeda for $3.2B.

FDA approvals

Did the clinical or FDA work on these 9 approvals.

Approved after he had moved on

Sculptra (PMA team; approved 2004), Solosec (due diligence; approved 2017), and Impleko (his concept; approved 2020).

Each tile opens the FDA record. NDA: New Drug Application. BLA: Biologics License Application. PMA: Premarket Approval.

Patents and publications

17 Orange Book patents for ColcrysInventor on all 17, sole inventor on 15. Eleven were granted within 12 months of filing.
US 7,601,758Colchicine dosing and drug interactionsOct 13, 2009
US 7,619,004Concomitant administration with macrolidesNov 17, 2009
US 7,820,681Prophylaxis of gout flaresOct 26, 2010
US 7,906,519Concomitant administration of colchicineMar 15, 2011
US 7,915,269Concomitant administration of colchicineMar 29, 2011
US 7,935,731Colchicine dosing during macrolide therapyMay 3, 2011
US 7,964,647Ultrapure colchicine compositionsJun 21, 2011
US 7,964,648Concomitant administration dosing methodsJun 21, 2011
US 7,981,938Colchicine compositions and methodsJul 19, 2011
US 8,093,296Concomitant administration, clinical methodsJan 10, 2012
US 8,093,297Concomitant administration (ketoconazole, ritonavir)Jan 10, 2012
US 8,093,298Colchicine and macrolidesJan 10, 2012
US 8,097,655Drug interaction alerts and dispensing warningsJan 17, 2012
US 8,415,395Ultrapure colchicine compositionsApr 9, 2013
US 8,415,396Colchicine compositions and methodsApr 9, 2013
US 8,440,721Concomitant administration, dosing guidanceMay 14, 2013
US 8,440,722Drug-drug interaction alert systemsMay 14, 2013
Selected publicationsPublished work cited more than 1,100 times.

Colchicine: the evidence behind Colcrys

Arthritis & Rheumatism, 2010
High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.
Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. View
Cited in the 2012 American College of Rheumatology gout guidelines, which recommend the regimen this trial tested: 1.2 mg followed by 0.6 mg one hour later.
Arthritis & Rheumatism, 2011
Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors.
Terkeltaub RA, Furst DE, DiGiacinto JL, Kook KA, Davis MW. View
Advances in Therapy, 2012
Are dosing adjustments required for colchicine in the elderly compared with younger patients?
Wason S, Faulkner RD, Davis MW. View
Clinical Therapeutics, 2012
Effects of grapefruit and Seville orange juices on the pharmacokinetic properties of colchicine in healthy subjects.
Wason S, DiGiacinto JL, Davis MW. View
International Journal of Immunopathology and Pharmacology, 2012
Pharmacokinetics of colchicine in pediatric and adult patients with familial Mediterranean fever.
Berkun Y, Wason S, Brik R, Butbul Y, Ben-Chetrit E, Hashkes PJ, Livneh A, Ozen S, Ozdogan H, Faulkner R, Davis MW.

Lidoderm

Annals of Pharmacotherapy, 2002
Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing.
Gammaitoni AR, Davis MW. View
Pain Medicine, 2002
Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial.
Katz NP, Gammaitoni AR, Davis MW, Dworkin RH. View

Regulatory policy

Advances in Therapy, 2011
Unapproved drugs in the United States and the Food and Drug Administration.
Nasr A, Lauterio TJ, Davis MW. View

Contact

mwd at mwdavis dot llc

linkedin.com/in/mwd-rph-md